

PU3375USW

~~3~~<sup>30</sup>. (New) A method of treatment according to claim ~~28~~<sup>2</sup> wherein alosetron is in the form of its hydrochloride.

~~4~~<sup>31</sup>. (New) A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof.

~~5~~<sup>32</sup>. (New) A method of treatment of diarrhea-predominant female IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof.

~~6~~<sup>33</sup>. (New) A method of treatment according to claim ~~32~~<sup>5</sup>, wherein alosetron is in the form of its hydrochloride.

*Cl cont*  
~~7~~<sup>34</sup>. (New) A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of a 5-HT<sub>3</sub> receptor antagonist or a pharmaceutically acceptable derivative thereof selected from the group consisting of granisetron, azasetron, tropisetron, ramosetron, ondansetron, lerisetron, (R) zacopride, cilansetron, itasetron, indisetron and dolasetron and pharmaceutically acceptable derivatives thereof.

~~8~~<sup>35</sup>. (New) A method of treatment of alternating constipation/diarrhea IBS which comprises administering an effective amount of alosetron or a pharmaceutically acceptable derivative thereof.

~~9~~<sup>36</sup>. (New) A method of treatment according to claim ~~35~~<sup>8</sup>, wherein alosetron is in the form of its hydrochloride.

Remarks

Currently Claims 28-36 are pending. Claims 5-8 and 11-18 are canceled in favor of the newly added claims. Claims 19-27 are canceled subject to Applicants' right to file one or more divisional applications directed thereto.